newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID

Potential to play leading role in addressing Long COVID fatigue and muscle weakness via AXA1125's mitochondrial and bioenergetic impact Phase 2a clinical trial to be initiated by researchers at Oxford University by year-end; top-line data readout